Bullish case
$72.50 to $73.00
More likely if shareholders approve the transaction, regulatory review clears, and the market prices a closing window in late 2026 or early 2027 with almost no remaining spread to the $73 cash offer.
Bio-Techne Corporation research snapshot
TECH AI Stock Analysis
TECH AI stock analysis reads Bio-Techne Corporation as a life science tools and diagnostics company whose stock is now a merger-spread trade ahead of the Merck KGaA cash acquisition at $73 per share. At the August 2, 2026 data cutoff, TECH closed near $72.09 on July 31, 2026, about 1.3% below the offer, with a market capitalization near $11.23 billion and the shareholder vote proxy on file. The analysis is a scenario framework around deal completion, regulatory approval, and standalone business quality. It is informational only and not investment advice.
Current price
$72.09
Market cap
$11.23 billion
AI score
72 / 100
Rating
Merger-spread convergence, tight to the $73 cash offer
Trend status
Uptrend above all key moving averages, near the deal price
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Bio-Techne has long public filings, current quarterly reports, investor releases, fresh merger documentation, and multiple analyst datasets.
- bias Check
- The main AI bias risk is treating the tight spread to the $73 cash offer as a near-certainty of closing. The reverse check separates merger-spread behavior from what the business would be worth if the deal is delayed, repriced, or fails.
- ai Confidence
- High for quote snapshots, filings, merger terms, valuation math, and analyst data. Medium for approval timing and final closing outcomes because regulatory and shareholder milestones can shift.
- investment Certainty
- Medium. Public data is strong and the spread is narrow, but upside is capped at the $73 cash consideration while a deal break or material delay would reset the stock toward standalone valuation.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Bio-Techne sells life science reagents, analytical technologies, diagnostics, spatial biology tools, and consumables used by research, biopharma, and diagnostic customers. | High |
| Moat | The moat comes from specialized protein science products, trusted research reagents, workflow integration, recurring consumables, and application know-how. | Medium-high |
| Management | CEO Kim Kelderman has led Bio-Techne since February 2024 after operating roles inside Bio-Techne and prior leadership experience at Thermo Fisher Scientific. | High |
| Financial trend | Fiscal 2025 sales rose 5% to $1.220 billion, while Q3 fiscal 2026 revenue fell 2% to $311.4 million with adjusted EPS of $0.53, reflecting mixed end-market demand. | High |
| Valuation | Standalone valuation is rich on GAAP earnings, but the announced $73 cash offer now anchors the price until deal risk changes. | Medium-high |
| Technical trend | TECH is in an uptrend above its 20-day, 50-day, and 200-day moving averages, with 14-day RSI near 74.6 and the stock close to its 52-week high of $72.37. | Medium |
| Risk level | Main risks are regulatory delay, shareholder approval failure, deal termination or repricing, funding conditions, and weaker standalone demand if the transaction breaks. | Medium-high |
| AI confidence | High confidence for sourced facts, quote data, and merger terms. Lower confidence for the exact timing and outcome of approvals. | High data confidence |
| Investment certainty | Medium certainty because the page provides a research framework and scenario ranges, not a personalized buy, hold, or sell instruction. | Medium |
TECH AI stock forecast
TECH AI Stock Forecast Scenarios
The TECH AI stock forecast is event-driven. The $73 cash merger consideration sets the bullish reference point, while the downside case depends on what Bio-Techne would be worth if the transaction is delayed, repriced, or fails.
Base case
$70.50 to $72.50
More likely if the deal stays on track but investors keep a small spread for shareholder vote timing, regulatory review, and funding conditions.
Bearish case
$46.00 to $62.00
More likely if the transaction is blocked, terminated, or materially delayed, resetting TECH toward standalone valuation based on forward earnings and analyst low targets near $50.
TECH AI technical analysis
TECH AI Technical Analysis
TECH AI technical analysis starts from the $72.09 close on July 31, 2026 and the announced $73 cash consideration. The stock trades above its 20-day, 50-day, 100-day, and 200-day moving averages with 14-day RSI near 74.6 and a 14-day ADX near 59, but the 52-week high of $72.37 and the $73 offer cap near-term upside.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $72.09 | StockAnalysis.com close on July 31, 2026, the quote used for this page at the August 2, 2026 data cutoff. |
| Deal consideration | $73.00 cash per share | Merck KGaA announced this cash consideration on June 25, 2026, making it the primary upside reference while the agreement remains active. |
| Near support | $71.50 to $72.00 | The 20-day moving average sat near $71.56, a natural first pullback support zone before any deal-risk widening. |
| Next support | $62.00 to $63.00 | The 50-day moving average was near $62.34, a level that would matter if the deal were delayed or put at risk. |
| Near resistance | $72.40 to $73.00 | The 52-week high of $72.37 and the $73 offer form the ceiling; a move into this zone implies a higher completion probability. |
| 50-day moving average | $62.34 | StockAnalysis.com and Barchart reported the 50-day moving average near $62.34, well below the current price. |
| 200-day moving average | $59.63 | StockAnalysis.com and Barchart placed the 200-day trend line near $59.63, below the post-announcement price. |
| Momentum | RSI near 74.6, ADX near 59 | 14-day RSI was overbought near 74.6 and 14-day ADX near 59 confirmed a strong short-term trend after the takeover jump. |
| Volume | About 4.1 million average shares | 20-day average volume was near 4.1 million shares, elevated versus the pre-deal baseline and reflecting merger-arbitrage flows. |
| Volatility | Low near-term, high around the deal | 14-day historical volatility was near 5% while 50-day volatility was near 50%, reflecting the calm after the takeover spike. |
| Invalidation | Sustained close below $71.50 | A decisive close below the 20-day moving average would signal rising deal risk; a move below the 50-day near $62 would suggest transaction-break concern. |
TECH AI trading strategy
TECH AI Trading Strategy Framework
The TECH AI trading strategy is a rules-based research framework for an event-driven stock. It is not personalized advice and should be paired with position sizing, deal-document review, and a predefined loss limit.
Deal-spread setup
Compare the trading price with the $73 cash consideration, the expected closing window in late 2026 or early 2027, shareholder vote timing, and regulatory milestones.
Exit or reduce confidence if the spread widens on negative approval news, deal terms change, or the timeline slips materially.
Momentum continuation setup
Watch for TECH to hold above the 20-day moving average near $71.56 and to approach the $72.40 to $73.00 resistance as completion probability rises.
Do not chase the stock near the offer price without accounting for the thin remaining spread and the risk that a higher bid never appears.
Standalone fallback monitor
Track life science tools demand, Protein Sciences growth, Diagnostics and Spatial Biology margin progress, cash generation, and debt reduction.
If the transaction breaks, reset valuation from standalone forward earnings and free cash flow rather than the $73 offer.
Investment research summary
Four-master Research Compression
Business essence
Bio-Techne helps researchers, biopharma companies, and diagnostics customers run specialized biological workflows through reagents, instruments, assays, and consumables.
Moat
The moat is based on trusted catalog depth, specialized protein science, workflow integration, consumable repeat usage, and customer validation costs in regulated scientific work.
Munger risk inversion
The thesis can fail if the Merck KGaA transaction is blocked, delayed, or repriced, or if standalone life science tools demand weakens before closing.
Management
Kim Kelderman became CEO in February 2024 after running Bio-Techne operating units and serving as COO. The merger agreement is now the central capital allocation decision.
Industry trend
Life science tools, protein analytics, spatial biology, diagnostics, and cell and gene therapy workflows remain long-duration markets, but customer budgets can cycle with biotech funding.
Valuation and margin of safety
The $73 cash offer limits upside if completed, while standalone valuation remains sensitive to GAAP earnings quality, adjusted margin durability, and the return of organic growth.
Source-backed data
TECH Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TECH price | $72.09, up 0.08% on July 31, 2026 | StockAnalysis.com quote snapshot | July 31, 2026 |
| Market capitalization | $11.23 billion, verified with financial_rigor.py at 0.03% variance using $72.09 and 155.83 million shares | StockAnalysis.com share data and financial_rigor.py | August 2, 2026 |
| Merger consideration | $73.00 per share in cash, total enterprise value near $11.3 billion | Merck KGaA acquisition announcement | June 25, 2026 |
| Merger premium | 36% premium to Bio-Techne one-month volume weighted average price | Merck KGaA acquisition announcement | June 25, 2026 |
| Expected closing window | Late 2026 to early 2027, subject to shareholder and regulatory approval | Merck KGaA and Bio-Techne deal announcement | June 25, 2026 |
| Proxy statement for shareholder vote | Schedule 14A proxy filed on July 9, 2026 | StockAnalysis.com filings | July 9, 2026 |
| Fiscal 2025 net sales | $1.219635 billion, up 5% from fiscal 2024 | Bio-Techne fiscal 2025 Form 10-K | July 8, 2026 |
| Fiscal 2025 GAAP net earnings | $73.4 million attributable to Bio-Techne | Bio-Techne fiscal 2025 Form 10-K | July 8, 2026 |
| Q3 fiscal 2026 revenue | $311.4 million, down 2% year over year | Bio-Techne Q3 fiscal 2026 release | May 6, 2026 |
| Q3 fiscal 2026 EPS | GAAP EPS $0.32, adjusted EPS $0.53 | Bio-Techne Q3 fiscal 2026 release | May 6, 2026 |
| TTM revenue and EPS | TTM revenue $1.211 billion, TTM GAAP EPS $0.69 | StockAnalysis.com financials | July 31, 2026 |
| Cash and investments | $214.11 million as of March 31, 2026 | Bio-Techne March 2026 Form 10-Q and StockAnalysis.com | August 2, 2026 |
| Total debt | $290.32 million as of March 31, 2026 | StockAnalysis.com balance sheet | August 2, 2026 |
| Net cash | -$76.21 million, calculated as cash and investments minus debt | financial_rigor.py exact calculator | August 2, 2026 |
| TTM free cash flow | $269.60 million, with FCF yield of 2.40% | StockAnalysis.com cash flow statement | August 2, 2026 |
| Valuation check | 103.77x trailing EPS, 9.28x sales, 41.67x free cash flow, 0.44% dividend yield | financial_rigor.py valuation verification and StockAnalysis.com | August 2, 2026 |
| Forward valuation | 36.03x forward PE, EV/EBITDA 44.51, EV/FCF 41.95 | StockAnalysis.com statistics | August 1, 2026 |
| Analyst consensus | Hold with an average target of $69.73 across 14 analysts, low $50 and high $73, median $73 | StockAnalysis.com forecast and analyst ratings | July 23, 2026 |
| Analyst rating mix, July 2026 | 2 Strong Buy, 0 Buy, 13 Hold, 0 Sell, 0 Strong Sell out of 15 | StockAnalysis.com forecast recommendation trends | July 23, 2026 |
| Recent analyst target updates | RBC Capital $62 to $73 Hold, TD Cowen $65 to $73 Hold, Citi $70 to $73 Hold, Stephens $68 to $73 Hold, Baird $49 to $73 Neutral | StockAnalysis.com forecast latest forecasts and TipRanks | July 23, 2026 |
| Short interest | 12.12 million shares short, 7.78% of shares outstanding, 1.51 days to cover | StockAnalysis.com statistics short selling | August 1, 2026 |
| 2026 and 2027 consensus estimates | FY2026 revenue estimate $1.21B with adjusted EPS $1.92, FY2027 revenue $1.26B with adjusted EPS $2.04 | StockAnalysis.com forecast financial forecast | July 23, 2026 |
| Next earnings date | August 5, 2026 for fiscal Q4 2026, consensus near $317 million revenue | StockAnalysis.com and Yahoo Finance earnings calendar | August 2, 2026 |
| Technical snapshot | 50-day SMA near $62.34, 200-day SMA near $59.63, RSI near 74.6, 14-day ADX near 59 | Barchart and StockAnalysis.com technical snapshots | July 31, 2026 |
Frequently Asked Questions
Read the NVDA AI stock analysisView GOOGL AI stock forecastExplore INTC AI technical analysisCompare ideas in AI Stock PickerBuild a rules-based trading strategyScreen stocks with Pineify
This TECH AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a promise of return. Forecast ranges are scenarios based on available public data as of August 2, 2026 and can be wrong if market prices, financial results, merger terms, regulatory facts, or company disclosures change.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Open
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Open
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Open